<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Acute simple cystitis in adult and adolescent females</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Acute simple cystitis in adult and adolescent females</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Acute simple cystitis in adult and adolescent females</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kalpana Gupta, MD, MPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen B Calderwood, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Khalil G Ghanem, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allyson Bloom, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H899949128"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Urinary tract infections (UTIs) include cystitis (infection of the bladder/lower urinary tract) and pyelonephritis (infection of the kidney/upper urinary tract). In females, the pathogenesis of UTIs begins with colonization of the vaginal introitus by uropathogens from the fecal flora, followed by ascension via the urethra into the bladder and, in the case of pyelonephritis, to the kidneys via the ureters. </p><p>This topic will review the approach to females with typical symptoms of cystitis when there is no concern that the infection has extended beyond the bladder. We consider this to be acute simple cystitis. <span class="utd-adt-cnt utd-adt-pathwys utd-content-120491">(Related Pathway(s):  <a class="utd-content-120491" href="/pathway/120491?topicRef=8063&amp;source=see_link">Urinary tract infection (UTI): Empiric antibiotic selection for acute simple cystitis in female adults</a>.)</span></p><p>When there is concern that the infection has possibly extended beyond the bladder (eg, when there is flank pain or other features suggestive of pyelonephritis, fever, and/or other signs of systemic illness, including sepsis) we consider this to be a complicated UTI. This approach to categorizing UTI  (<a class="graphic graphic_table graphicRef117508" href="/z/d/graphic/117508.html" rel="external">table 1</a>) differs from other conventions, as discussed in detail below.</p><p>Our approach to the diagnosis and management of complicated UTI is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents"</a>.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-120490">(Related Pathway(s):  <a class="utd-content-120490" href="/pathway/120490?topicRef=8063&amp;source=see_link">Urinary tract infection (UTI): Empiric antibiotic selection for acute complicated UTI in adults</a>.)</span></p><p>Additionally, acute simple cystitis in men and UTIs in special populations are discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8059.html" rel="external">"Acute simple cystitis in adult and adolescent males"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8065.html" rel="external">"Urinary tract infections and asymptomatic bacteriuria in pregnancy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8054.html" rel="external">"Catheter-associated urinary tract infection in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7298.html" rel="external">"Urinary tract infection in kidney transplant recipients"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8053.html" rel="external">"Recurrent simple cystitis in women"</a>.)</p><p></p><p>Asymptomatic bacteriuria is also discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8061.html" rel="external">"Asymptomatic bacteriuria in adults"</a>.)</p><p>Urinary tract infection in children is also discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5988.html" rel="external">"Urinary tract infections in children: Epidemiology and risk factors"</a> and  <a class="medical medical_review" href="/z/d/html/6066.html" rel="external">"Urinary tract infections in children: Long-term management and prevention"</a> and  <a class="medical medical_review" href="/z/d/html/5990.html" rel="external">"Urinary tract infections in infants and children older than one month: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5991.html" rel="external">"Urinary tract infections in infants older than one month and children less than two years: Acute management, imaging, and prognosis"</a>.)</p><p class="headingAnchor" id="H3308263302"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>We use the term acute simple cystitis to refer to an acute urinary tract infection (UTI) that is presumed to be confined to the bladder  (<a class="graphic graphic_table graphicRef117508" href="/z/d/graphic/117508.html" rel="external">table 1</a>). Such infections <strong>lack</strong> signs or symptoms that suggest an infection extending beyond the bladder, which include: </p><p class="bulletIndent1"><span class="glyph">●</span>Fever (&gt;99.9°F/37.7°C) – This temperature threshold is not well defined and should be individualized, taking into account baseline temperature, other potential contributors to an elevated temperature, and the risk of poor outcomes should empiric antimicrobial therapy be inappropriate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other signs or symptoms of systemic illness (including chills or rigors, significant fatigue or malaise beyond baseline).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Flank pain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Costovertebral angle tenderness. </p><p></p><p>If any of these signs or symptoms are present in the setting of pyuria and bacteriuria, we consider the patient to have acute complicated UTI and manage the patient differently. By this definition, pyelonephritis is a complicated UTI, regardless of patient characteristics. (See  <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents"</a>.)</p><p>We do not automatically consider patients with underlying urologic abnormalities (such as nephrolithiasis, strictures, stents, or urinary diversions), immunocompromising conditions (such as neutropenia or advanced HIV infection), or poorly controlled diabetes mellitus to have a complicated UTI if they have no concerning symptoms for upper tract or systemic infection. However, such patients can be at higher risk for more serious infection and have not traditionally been included in studies evaluating the antibiotic regimens we typically use for acute simple cystitis. Thus, we follow such patients more closely and/or have a low threshold to manage them as complicated UTI (eg, if they have subtle signs or symptoms that could be suggestive of more extensive infection). Many patients with significant urologic abnormalities come to clinical attention for UTI because of signs or symptoms consistent with complicated UTI as defined here (rather than features of simple cystitis alone). </p><p>Certain populations, such as pregnant individuals and renal transplant recipients, have unique management considerations and thus are not included in the above categorization. These populations are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8065.html" rel="external">"Urinary tract infections and asymptomatic bacteriuria in pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/7298.html" rel="external">"Urinary tract infection in kidney transplant recipients"</a>.)</p><p>These definitions of acute simple cystitis and complicated UTI are different from other categorizations, which themselves are somewhat variable. Specifically, cystitis or pyelonephritis in a nonpregnant premenopausal woman without underlying urologic abnormalities has traditionally been termed acute uncomplicated UTI [<a href="#rid1">1</a>], and complicated UTI has been defined, for the purposes of treatment trials, as cystitis or pyelonephritis in a patient with underlying urologic abnormalities. Individuals who do not fit into either category have often been treated as having a complicated UTI by default. Rather than use this convention, we favor an approach to treatment based on the presumed extent of infection and severity of illness. Since complicated UTI, as defined here, is a more serious infection than simple cystitis, the efficacy of an antimicrobial agent is of greater importance, and certain agents used for simple cystitis should not be used for complicated UTI because they do not achieve adequate levels in tissue, which may be important for cure. Risk for infection with drug-resistant organisms is a consideration in antibiotic selection for both simple cystitis and acute complicated UTI. </p><p>Females categorized as having acute uncomplicated cystitis according to the traditional definition would fall under the definition of acute simple cystitis that we use here. </p><p class="headingAnchor" id="H2695791268"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Cystitis among females is extremely common [<a href="#rid2">2,3</a>]. The shorter distance from the anus to the urethra likely explains why females are at higher risk for urinary tract infections (UTIs) than men. </p><p>Among otherwise healthy females, risk factors for cystitis include recent sexual intercourse and a history of UTI [<a href="#rid4">4,5</a>]. Use of spermicide-coated condoms, diaphragms, and spermicides alone are also associated with an increased cystitis risk. </p><p>Other comorbidities, such as diabetes mellitus and structural or functional urinary tract abnormalities, can also increase the risk of cystitis [<a href="#rid2">2</a>]. Although patients with these comorbidities have traditionally been categorized as having complicated UTI, our approach does not necessarily categorize them as such. </p><p class="headingAnchor" id="H899949156"><span class="h1">MICROBIOLOGY</span></p><p class="headingAnchor" id="H3697403935"><span class="h2">Microbial spectrum</span><span class="headingEndMark"> — </span><em>Escherichia coli</em> is the most frequent microbial cause of simple cystitis (75 to 95 percent of cases), with occasional infections caused by other species of Enterobacteriaceae (such as <em>Klebsiella pneumoniae</em> and <em>Proteus mirabilis</em>) and other bacteria, such as <em>Staphylococcus saprophyticus</em> [<a href="#rid6">6,7</a>]. Other gram-negative and gram-positive species are infrequently isolated in acute simple cystitis in the absence of antimicrobial or health care exposures. </p><p>The microbial spectrum of simple cystitis in patients with recent antimicrobial or other health care exposures may be broader and also includes other gram-negative bacilli (eg, <em>Pseudomonas</em>), enterococci, and staphylococci. Thus, culture and susceptibility testing are essential for management in patients who have such risk factors  (<a class="graphic graphic_table graphicRef114310" href="/z/d/graphic/114310.html" rel="external">table 2</a>). Even in the absence of specific risk factors, resistance in <em>E. coli</em> can be a major issue. </p><p>Among otherwise healthy nonpregnant females, the isolation of organisms such as lactobacilli, enterococci, Group B streptococci, and coagulase-negative staphylococci other than <em>S. saprophyticus</em> from voided midstream urine most commonly represents contamination of the urine specimen [<a href="#rid8">8,9</a>]. Nevertheless, it may be appropriate to consider these organisms the likely causative agent in symptomatic females when found in voided midstream urine at high counts and with pure growth (ie, without growth of other bacteria). That such organisms are rarely the cause of acute simple cystitis in such females is supported by a study of 202 premenopausal, nonpregnant females with acute cystitis who collected a midstream, clean-catch urine, and subsequently underwent urethral catheterization to collect a bladder urine specimen [<a href="#rid10">10</a>]. There was high concordance between growth on voided and catheterized specimens for <em>E. coli</em> (even at counts as low as 10 colony-forming units [CFU]/mL), <em>K. pneumoniae</em>, and <em>S. saprophyticus</em>. In contrast, enterococci and Group B streptococci were isolated from 20 and 25 voided specimens, respectively, but only from two corresponding catheterized specimens each. In the majority of specimens with these organisms, growth was &lt;10<sup>4</sup> CFU/mL, and <em>E. coli</em> was also isolated. </p><p class="headingAnchor" id="H899949163"><span class="h2">Resistance trends in E. coli</span><span class="headingEndMark"> — </span>Expected susceptibility patterns of <em>E. coli</em> should inform the empiric antimicrobial selection for cystitis. Increasing rates of resistance have been reported globally. Risk factors for urinary tract infection (UTI) with resistant organisms include recent broad-spectrum antimicrobial use, health care exposures, and travel to parts of the world where multidrug-resistant organisms are prevalent [<a href="#rid11">11-15</a>]  (<a class="graphic graphic_table graphicRef114310" href="/z/d/graphic/114310.html" rel="external">table 2</a>). Ongoing monitoring of local prevalence of resistance is necessary for optimization of empiric therapy. (See <a class="local">'Empiric antimicrobial selection'</a> below.)</p><p>The in vitro susceptibility of <em>E. coli</em> varies considerably by geographic region. In four large studies, overall resistance rates were higher in medical centers in the United States than in Canada, and higher in Portugal and Spain than in other European countries [<a href="#rid16">16-19</a>]. In general, resistance rates &gt;20 percent were reported in all regions for <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a> and in many regions for <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">trimethoprim</a> (with or without sulfamethoxazole). </p><p><a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">Nitrofurantoin</a>, <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">fosfomycin</a>, and <a class="drug drug_general" data-topicid="118047" href="/z/d/drug information/118047.html" rel="external">pivmecillinam</a> (the last is not available in the United States) have demonstrated good in vitro activity in all countries investigated [<a href="#rid16">16-19</a>] and are thus appropriate first-line agents for acute simple cystitis when there are no clear risk factors for resistance [<a href="#rid1">1</a>]. </p><p>Resistance rates for first and second generation oral cephalosporins and amoxicillin-clavulanic acid are regionally variable but generally &lt;10 percent. </p><p>Fluoroquinolone resistance rates have been &lt;10 percent in most parts of North America and Europe, but there has been a clear trend of increasing resistance over time [<a href="#rid16">16-21</a>]. In a study of <em>E. coli</em> urinary isolates from outpatients in the United States, resistance rates to <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> increased from 3 to 17 percent between 2000 and 2010 [<a href="#rid20">20</a>]. In a population-based study of over 5000 <em>E. coli</em> urinary isolates collected in Minnesota between 2005 and 2009, the incidence of urinary isolates resistant to fluoroquinolones and/or <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX) increased among older adult patients and those with community-associated isolates, but not among health care-associated cases [<a href="#rid21">21</a>]. One caveat in interpreting these data is that passive laboratory-based surveillance methods tend to overestimate true resistance rates since they are skewed by urine cultures obtained from patients who may have failed initial therapy or who have specific risk factors for resistance, such as recent travel or antimicrobial use [<a href="#rid22">22-24</a>]. </p><p>TMP-SMX is the agent for which there are the most data to guide clinical use; identified risk factors for resistance in females with acute simple cystitis include use of TMP-SMX in the preceding three to six months and travel, particularly international travel [<a href="#rid25">25-28</a>]. In addition, clinical, in vitro, and mathematical modeling studies have suggested that a 20 percent resistance prevalence should be the threshold at which TMP-SMX should not be used for empiric treatment of acute simple cystitis [<a href="#rid29">29,30</a>].</p><p>For other antimicrobial agents, there are insufficient data to determine the resistance levels at which the likelihood of failure outweighs the potential benefits; the decision depends on individual practitioner discretion. In addition, it is important for clinicians to understand that local resistance rates reported in hospital antibiograms are often skewed by cultures of samples obtained from hospitalized patients or those with complicated infection and may not accurately predict susceptibilities in females with acute simple community-acquired cystitis, in whom resistance rates tend to be lower [<a href="#rid31">31,32</a>].</p><p>Nevertheless, resistant infections are increasing in number, including those caused by extended-spectrum beta-lactamase (ESBL)-producing strains. An increase in ESBL-producing isolates has been described among patients with acute simple cystitis worldwide [<a href="#rid33">33-35</a>]. In particular, a specific strain of <em>E. coli</em>, sequence type 131 (ST131), has emerged globally as a major cause of fluoroquinolone-resistant and ESBL-producing <em>E. coli</em> UTIs [<a href="#rid36">36</a>]. </p><p class="headingAnchor" id="H899949170"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The classic clinical manifestations of cystitis consist of dysuria, urinary frequency, urinary urgency, and suprapubic pain [<a href="#rid37">37</a>]. Hematuria is also often observed.</p><p>Symptoms of cystitis can occasionally be subtle and more difficult to tease out, particularly in older females. Older females can have a number of nonspecific urinary symptoms (such as chronic dysuria or urinary incontinence) that mimic symptoms of cystitis, even when there is no evidence of urinary tract infection (UTI). A systematic review of studies evaluating the diagnosis of UTI among community-dwelling adults older than 65 years suggested that symptoms such as chronic urinary nocturia, incontinence, and general sense of lack of well-being were common and nonspecific for UTI [<a href="#rid38">38</a>]. In contrast, acute dysuria (less than one week duration), new or worsening urinary urgency, new incontinence, frequency, gross hematuria, and suprapubic pain or tenderness were more discriminating symptoms. Fever was also a discriminating feature, although we consider patients with cystitis symptoms and fever to have a complicated UTI. (See  <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents", section on 'Clinical manifestations'</a>.)</p><p>Similarly, among debilitated patients, many generalized signs or symptoms, such as falls, change in functional status, and change in mental status, are frequently attributed to UTI, but growing evidence indicates that these are not reliable predictors of bacteriuria or cystitis. In one cohort study of nursing home residents, among clinical features that prompted evaluation for UTI (including change in gait or falls, change in functional status, fever or chills), only acute dysuria, change in the character of urine (gross hematuria, change in color or odor), and change in mental status were associated with the presence of both pyuria and bacteriuria [<a href="#rid39">39</a>]. However, other studies that controlled for comorbidities have found no association between bacteriuria in nursing home patients and nonspecific mental status changes (such as increased restlessness, confusion, or aggression) [<a href="#rid40">40</a>]. Among those with bacteriuria, there also appears to be no association between these nonspecific mental status changes and urinary markers of inflammation (ie, interleukin-6) [<a href="#rid41">41</a>]. Furthermore, treatment of bacteriuria in patients with acute delirium or nonspecific symptoms is not associated with improvement in mental or functional status (but is associated with <em>Clostridioides </em>[formerly <em>Clostridium</em>]<em> difficile </em>infection) [<a href="#rid42">42,43</a>].</p><p>Although cloudy or smelly urine may be associated with bacteriuria (as demonstrated in nursing home residents [<a href="#rid39">39</a>]), there is no evidence of benefit to treating patients with only these complaints as having a UTI prior to onset of usual cystitis symptoms. Color and odor of urine are influenced by ingestion of certain foods, dehydration, and other noninfectious factors. Thus, increased fluid intake and careful observation are reasonable initial approaches to patients who complain of changes in odor or color of urine.</p><p>Fever, chills, rigors, and other signs of systemic illness are not compatible with a diagnosis of acute simple cystitis and raise the possibility of pyelonephritis or other complication of UTI. (See  <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents"</a>.)</p><p class="headingAnchor" id="H899949177"><span class="h1">DIAGNOSTIC APPROACH</span></p><p class="headingAnchor" id="H1530531830"><span class="h2">Clinical suspicion and evaluation</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to suspect cystitis and perform urine testing to support the diagnosis</strong> – The approach depends on the presenting symptoms.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Individuals with typical cystitis symptoms</strong> – Acute simple cystitis should be suspected in females who have acute symptoms of dysuria, urinary frequency or urgency, and/or suprapubic pain, particularly in the absence of vaginal symptoms (eg, vaginal pruritus or discharge). The probability of cystitis is greater than 50 percent in females with any of these symptoms and greater than 90 percent in females who have dysuria and frequency without vaginal discharge or irritation [<a href="#rid37">37</a>]. </p><p></p><p class="bulletIndent2">For individuals who present with such symptoms for the first time, we typically obtain urine studies to establish the diagnosis. Subsequently, however, urine testing is not necessary to reconfirm the diagnosis in the setting of typical cystitis symptoms. (See <a class="local">'Performing and interpreting urine studies'</a> below.)</p><p></p><p class="bulletIndent2">Although urine culture and susceptibility testing are also usually unnecessary for management in most females with acute simple cystitis, we perform them in patients who are at risk for infection with a resistant organism  (<a class="graphic graphic_table graphicRef114310" href="/z/d/graphic/114310.html" rel="external">table 2</a>). We also check culture and susceptibility testing on patients with risk factors for more serious infection, such as those with underlying urologic abnormalities, immunocompromising conditions, and poorly controlled diabetes, regardless of other risk factors for resistance. (See <a class="local">'Urine culture'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Individuals with atypical urinary symptoms</strong> – Acute simple cystitis is often suspected in females with atypical urinary symptoms that could be suggestive of cystitis but are not clearly diagnostic. These include acute on chronic dysuria and urgency or new or worsening incontinence. In such cases, we check urinalysis and urine culture to help support the diagnosis, as the absence of pyuria on urinalysis or bacteriuria on culture suggests a diagnosis other than cystitis. When indicated, urinalysis can be performed either by microscopy or by dipstick. (See <a class="local">'Urinalysis'</a> below.)</p><p></p><p class="bulletIndent2">In contrast, chronic urinary nocturia, chronic incontinence, and cloudy or malodorous urine are nonspecific urinary findings that should not routinely prompt urine testing to evaluate for cystitis. Patients with hematuria in the absence of other urinary symptoms do not warrant urine culture to evaluate for bacteriuria unless no other etiology is identified.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Individuals with nonspecific symptoms</strong> – Urinary tract infection (UTI) is often suspected in older or debilitated patients with general malaise and nonspecific changes in mental, behavior, or functional status. However, in the absence of focal urinary tract symptoms or systemic symptoms of infection, these nonspecific features are not predictive of cystitis [<a href="#rid40">40-42</a>]. In such cases, we do not routinely test urine to evaluate for UTI but instead hydrate, carefully observe, and assess other potential contributing factors [<a href="#rid44">44</a>]. If fever is also present, evaluation for infection, including complicated UTI, is warranted. (See  <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents"</a>.). </p><p></p><p class="bulletIndent2">The evaluation and diagnosis of UTI in older adults are further discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/14606.html" rel="external">"Approach to infection in the older adult", section on 'Urinary tract infection'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional evaluation </strong>–<strong> </strong>Individuals with suspected cystitis should be asked about fevers/chills and flank pain. Physical examination is often not necessary for the diagnosis, but if performed, should include assessment for fever, costovertebral angle tenderness, and abdominal tenderness. A pelvic examination is indicated if symptoms or signs suggesting vaginitis or urethritis are present. </p><p></p><p class="bulletIndent1">If fever (&gt;99.9°F/37.7°C), other signs or symptoms of systemic illness (including chills, rigors, or marked fatigue or malaise beyond baseline), flank pain, or costovertebral angle tenderness are present, the patient should be evaluated and managed as potentially having complicated UTI, which is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents"</a>.)</p><p></p><p class="bulletIndent1">Pregnancy testing is appropriate in individuals of childbearing potential when the possibility of pregnancy cannot be reasonably excluded by history alone.</p><p></p><p class="bulletIndent1">Blood testing is not warranted for patients with acute simple cystitis.</p><p></p><p class="headingAnchor" id="H3119698267"><span class="h2">Performing and interpreting urine studies</span></p><p class="headingAnchor" id="H2040400407"><span class="h3">Specimen collection</span><span class="headingEndMark"> — </span>Details on optimal urine collection when UTI is suspected are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8056.html" rel="external">"Sampling and evaluation of voided urine in the diagnosis of urinary tract infection in adults", section on 'Urine sampling'</a>.)</p><p class="headingAnchor" id="H899949184"><span class="h3">Urinalysis</span><span class="headingEndMark"> — </span>Urinalysis (either by microscopy or by dipstick) for evaluation of pyuria is a valuable laboratory diagnostic test for UTI. It is not indicated in females with typical symptoms of acute simple cystitis (in whom the diagnosis can reliably be made on symptoms alone), but it can be helpful in cases in which the clinical presentation is not typical. Pyuria is present in almost all females with acute cystitis; its absence strongly suggests an alternative diagnosis [<a href="#rid45">45,46</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>The most accurate method for assessing pyuria is to examine an unspun, voided midstream urine specimen under the microscope with a hemocytometer; an abnormal result is ≥10 leukocytes/microL [<a href="#rid45">45</a>]. However, this laboratory test is usually not available to the clinician. The presence of hematuria is helpful since it is common in the setting of UTI but not in urethritis or vaginitis. However, hematuria is not a predictor for complicated infection and does not alter the approach to therapy. White blood cell casts in the urine, although rare, are indicative of upper tract infection rather than simple cystitis. (See  <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents", section on 'Diagnostic approach'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dipsticks are commercially available strips that detect the presence of leukocyte esterase (an enzyme released by leukocytes, reflecting pyuria) and nitrite (reflecting the presence of Enterobacteriaceae, which convert urinary nitrate to nitrite). The dipstick test is most accurate for predicting UTI when positive for either leukocyte esterase or nitrite, with a sensitivity of 75 percent and a specificity of 82 percent [<a href="#rid37">37</a>]. However, results of the dipstick test provide little useful information when the clinical history is strongly suggestive of UTI, since even negative results for both tests do not reliably rule out infection in such cases. </p><p></p><p>Additional details on urine testing (with microscopy for pyuria and dipstick) are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8056.html" rel="external">"Sampling and evaluation of voided urine in the diagnosis of urinary tract infection in adults"</a>.)</p><p class="headingAnchor" id="H899949191"><span class="h3">Urine culture</span><span class="headingEndMark"> — </span>The causative organisms and their antimicrobial susceptibility profiles are frequently predictable in females with acute simple cystitis, and thus routine cultures for such infections are often not necessary for management decisions. However, given the increasing prevalence of antimicrobial resistance among uropathogens, obtaining a urine culture prior to initiation of therapy is warranted in patients who have risk factors for antimicrobial resistance  (<a class="graphic graphic_table graphicRef114310" href="/z/d/graphic/114310.html" rel="external">table 2</a>), as well as in patients at risk for more serious infection (eg, those with underlying urologic abnormalities, immunocompromising conditions, and poorly controlled diabetes mellitus).</p><p>If voided urine cultures are sent to the laboratory, the clinician should ask the laboratory to quantify <em>E. coli</em>, if it grows, to at least 10<sup>3</sup> colony-forming units/mL to improve specificity. Moreover, <em>E. coli</em> should not necessarily be considered a contaminant if it grows in mixed flora since almost any growth of <em>E. coli</em> in voided urine in a symptomatic patient reflects bladder growth [<a href="#rid10">10</a>]. Growth of organisms generally thought to be contaminants (such as lactobacilli, enterococci, Group B streptococci, and non-saprophyticus coagulase-negative staphylococci) may be considered causative when found in voided midstream urine at high counts and with pure growth (see <a class="local">'Microbiology'</a> above). </p><p>Issues related to interpretation of urine culture colony counts are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8056.html" rel="external">"Sampling and evaluation of voided urine in the diagnosis of urinary tract infection in adults", section on 'Definition of a positive culture'</a>.)</p><p class="headingAnchor" id="H385532615"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The clinical diagnosis of cystitis is made in a patient who has classic signs and symptoms (ie, dysuria, urinary frequency, urgency, and/or suprapubic pain). For females who have atypical urinary symptoms, the diagnosis is supported by the presence of pyuria and bacteriuria on urinalysis and/or culture. (See <a class="local">'Clinical suspicion and evaluation'</a> above.)</p><p>The clinical diagnosis of acute <strong>simple</strong> cystitis also excludes fever (&gt;99.9°F/37.7°C), other signs or symptoms of systemic illness (including chills, rigors, or marked fatigue or malaise beyond baseline), flank pain, and costovertebral angle tenderness  (<a class="graphic graphic_table graphicRef117508" href="/z/d/graphic/117508.html" rel="external">table 1</a>). The presence of any of these features suggests pyelonephritis or extension of the infection beyond the bladder, and we thus consider the patient to have an acute <strong>complicated</strong> UTI, which is discussed in detail elsewhere. We also have a lower threshold to consider patients with risk factors for more serious infection as having acute complicated UTI, for example, if they have more subtle signs or symptoms of possible upper tract or systemic infection. Such risk factors include urologic abnormalities (eg, nephrolithiasis, strictures, stents, or urinary diversions), immunocompromising conditions (eg, neutropenia or advanced HIV infection), or poorly controlled diabetes mellitus. (See  <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents"</a>.)</p><p>Bacteriuria with or without pyuria in the absence of any symptom that could be attributable to a UTI is called asymptomatic bacteriuria and generally does not warrant treatment in nonpregnant patients who are not undergoing urologic procedures. (See  <a class="medical medical_review" href="/z/d/html/8061.html" rel="external">"Asymptomatic bacteriuria in adults"</a>.)</p><p>The diagnosis of UTI in a patient with an indwelling urinary catheter is discussed in further detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8054.html" rel="external">"Catheter-associated urinary tract infection in adults", section on 'Diagnosis'</a>.) </p><p class="headingAnchor" id="H1425706"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Both infectious and noninfectious processes can cause symptoms of dysuria, frequency, urgency, suprapubic pain, and/or hematuria  (<a class="graphic graphic_table graphicRef143594" href="/z/d/graphic/143594.html" rel="external">table 3</a>) [<a href="#rid9">9</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Vaginitis – In females with dysuria, the presence of vaginal discharge or odor, pruritus, dyspareunia, and absence of urinary frequency or urgency should prompt consideration of vaginitis. Causes of vaginitis include yeast infection, trichomoniasis, and bacterial vaginosis. (See  <a class="medical medical_review" href="/z/d/html/5477.html" rel="external">"Vaginitis in adults: Initial evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urethritis – Evaluation for urethritis is warranted in sexually active females with dysuria, particularly those with pyuria on urinalysis but no bacteriuria. Causes of urethritis in females include chlamydia, gonorrhea, trichomoniasis, <em>Candida</em> species, herpes simplex virus, and noninfectious irritants, such as a contraceptive gel. (See  <a class="medical medical_review" href="/z/d/html/83019.html" rel="external">"Clinical manifestations and diagnosis of <i>Chlamydia trachomatis </i>infections", section on 'Dysuria-pyuria syndrome due to urethritis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Painful bladder syndrome – This is a diagnosis of exclusion in females who have ongoing discomfort related to the bladder with symptoms of dysuria, frequency, and/or urgency but no evidence of infection or other identifiable cause. (See  <a class="medical medical_review" href="/z/d/html/8085.html" rel="external">"Interstitial cystitis/bladder pain syndrome: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pelvic inflammatory disease – Lower abdominal or pelvic pain and fever are the most common clinical findings in patients with pelvic inflammatory disease (PID), although dysuria may also be present. The findings of mucopurulent endocervical discharge or cervical motion tenderness on pelvic examination are strongly suggestive of PID. (See  <a class="medical medical_review" href="/z/d/html/7581.html" rel="external">"Pelvic inflammatory disease: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H899949213"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H2761251353"><span class="h2">Empiric antimicrobial selection</span><span class="headingEndMark"> — </span>The selection of an antimicrobial regimen for acute simple cystitis  (<a class="graphic graphic_table graphicRef117508" href="/z/d/graphic/117508.html" rel="external">table 1</a>) depends on the risk of infection with a multidrug-resistant (MDR) gram-negative organism  (<a class="graphic graphic_algorithm graphicRef115993" href="/z/d/graphic/115993.html" rel="external">algorithm 1</a>). <span class="utd-adt-cnt utd-adt-pathwys utd-content-120491">(Related Pathway(s):  <a class="utd-content-120491" href="/pathway/120491?topicRef=8063&amp;source=see_link">Urinary tract infection (UTI): Empiric antibiotic selection for acute simple cystitis in female adults</a>.)</span></p><p>We generally consider patients to be higher risk for an MDR gram-negative organism if they have any of the following occurring in the prior three months:</p><p class="bulletIndent1"><span class="glyph">●</span>An MDR gram-negative urinary isolate (ie, nonsusceptible to at least one agent in three or more antimicrobial classes; this includes extended-spectrum beta-lactamase [ESBL]-producing isolates).</p><p class="bulletIndent1"><span class="glyph">●</span>Inpatient stay in a health care facility (eg, hospital, nursing home, long-term acute care facility).</p><p class="bulletIndent1"><span class="glyph">●</span>Use of a fluoroquinolone, <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, or broad-spectrum beta-lactam (eg, third or later generation cephalosporin) [<a href="#rid47">47</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Travel to parts of the world with high rates of MDR organisms (eg, India, Israel, Spain, Mexico).</p><p></p><p class="headingAnchor" id="H3563888118"><span class="h3">Patients without MDR risk factors</span><span class="headingEndMark"> — </span>For patients who do not have risk factors for an MDR gram-negative infection  (<a class="graphic graphic_table graphicRef114310" href="/z/d/graphic/114310.html" rel="external">table 2</a>), we typically choose one of the first-line antimicrobial regimens (<a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">nitrofurantoin</a> monohydrate/macrocrystals, <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">fosfomycin</a>, or <a class="drug drug_general" data-topicid="118047" href="/z/d/drug information/118047.html" rel="external">pivmecillinam</a>)  (<a class="graphic graphic_algorithm graphicRef115993" href="/z/d/graphic/115993.html" rel="external">algorithm 1</a>). (See <a class="local">'First-line antimicrobial options'</a> below.)</p><p>For patients who have reasons to avoid all these options (either because of allergies or intolerances or a history of a urinary isolate resistant to these agents within the prior three months), we choose an alternative option. (See <a class="local">'Alternative antimicrobial options'</a> below.) </p><p class="headingAnchor" id="H207461713"><span class="h4">First-line antimicrobial options</span><span class="headingEndMark"> — </span>The preferred agents for empiric therapy of acute simple cystitis are <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">nitrofurantoin</a> monohydrate/macrocrystals, <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">fosfomycin</a>, and, if available, <a class="drug drug_general" data-topicid="118047" href="/z/d/drug information/118047.html" rel="external">pivmecillinam</a> because of the favorable balance between efficacy and adverse effects (including the risk of selecting for resistant organisms) [<a href="#rid1">1</a>]. None of the first-line agents clearly outweighs the others in terms of the efficacy/adverse effects balance, with the exception that resistance is more likely with trimethoprim-sulfamethoxazole and that pivmecillinam (and possibly fosfomycin) is somewhat less effective; the optimal antimicrobial in one region may be different from that in another depending on resistance prevalence (see <a class="local">'Resistance trends in E. coli'</a> above). Thus, the choice among them should be individualized based on patient circumstances (allergy, tolerability, expected adherence), local community resistance prevalence, availability, cost, and patient and provider threshold for failure. If the patient has taken one of the agents in the preceding three months, a different one should be selected. </p><p>If all these are appropriate options based on patient circumstances and prior urinary isolates, we suggest <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">nitrofurantoin</a> or <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> rather than <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">fosfomycin</a> or <a class="drug drug_general" data-topicid="118047" href="/z/d/drug information/118047.html" rel="external">pivmecillinam</a>. Because fosfomycin retains activity against many MDR isolates and overuse may result in increasing rates of resistance, we favor reserving it for suspected MDR infections or when other first-line agents cannot be used. Pivmecillinam is somewhat less effective but is commonly used in Europe because of a low risk of selection for resistance. </p><p>Details on dosing, expected efficacy, and additional reasons for avoidance are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nitrofurantoin</strong><strong> monohydrate/macrocrystals (Macrobid) </strong>– Dosed at 100 mg orally twice daily for five days. Randomized trials suggest a 79 to 92 percent clinical cure rate with a five- to seven-day regimen, with minimal resistance promotion [<a href="#rid48">48-50</a>]. Higher rates of failure occurred with shorter courses [<a href="#rid51">51</a>]. It has minimal propensity to select for resistant organisms. <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">Nitrofurantoin</a> should be avoided if there is suspicion for early pyelonephritis or if the creatinine clearance is &lt;30 mL/minute. Observational studies have suggested that the agent is effective and safe with mild renal impairment, even in older females [<a href="#rid52">52-55</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trimethoprim-sulfamethoxazole</strong> – Dosed as one double-strength tablet (160/800 mg) orally twice daily for three days. Randomized trials suggest a 79 to 100 percent clinical cure rate with a three- to seven-day regimen [<a href="#rid48">48,56-58</a>]. Empiric <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> should be avoided if the regional prevalence of resistance is known to exceed 20 percent [<a href="#rid29">29,30</a>]. In some regions, <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">trimethoprim</a> (100 mg twice daily for three days) is used in place of trimethoprim-sulfamethoxazole and is considered equivalent [<a href="#rid59">59</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fosfomycin</strong> – Dosed as 3 g of powder mixed in water as a single oral dose. One randomized trial reported an early clinical cure rate of 91 percent and a bacterial cure rate similar to <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">nitrofurantoin</a> [<a href="#rid60">60</a>], and a meta-analysis demonstrated no difference in cure rates between <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">fosfomycin</a> and other agents, including fluoroquinolones, <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, and nitrofurantoin [<a href="#rid61">61</a>]. However, in a subsequent open-label trial, a single dose of fosfomycin resulted in lower clinical (58 versus 70 percent) and microbiologic (63 versus 74 percent) success rates at 28 days compared with nitrofurantoin given three times daily for five days [<a href="#rid62">62</a>]. Lower than expected clinical success rates in both groups may be a result of the definition used in this study (complete resolution of UTI signs and symptoms rather than improvement of signs and symptoms, as used in other trials). It is not clear whether the open-label trial design influenced the findings [<a href="#rid63">63</a>]. Susceptibility testing for fosfomycin is not routinely available in most clinical laboratories. Fosfomycin should be avoided if there is suspicion for early pyelonephritis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pivmecillinam</strong> – Doses used in studies range from 400 mg orally two or three times daily for three to seven days; we suggest a dose of 400 mg three times daily for three to five days. In one randomized trial of females with cystitis, the 400 mg three times daily dose given for three versus five days resulted in similarly high clinical (73 versus 76 percent) and microbiologic success rates (87 versus 88 percent) [<a href="#rid64">64</a>]. <a class="drug drug_general" data-topicid="118047" href="/z/d/drug information/118047.html" rel="external">Pivmecillinam</a> is a penicillin with an extended gram-negative spectrum, is used only for treatment of urinary tract infection (UTI) and has minimal propensity to select for resistant organisms [<a href="#rid65">65,66</a>]. It is not available in the United States but is an agent of choice in many Nordic countries due to low resistance rates [<a href="#rid67">67</a>]. Pivmecillinam should be avoided if there is suspicion for early pyelonephritis.</p><p></p><p>These antimicrobial options and suggested treatment durations for acute simple cystitis are the same for any adult woman with acute simple cystitis, regardless of age [<a href="#rid68">68</a>]. A systematic review of studies evaluating treatment of cystitis in community-dwelling adults ≥65 years of age concluded that the optimal regimens are the same as those recommended for younger adults and that shorter antimicrobial courses (three to six days) resulted in similar outcomes as longer ones (7 to 14 days) [<a href="#rid69">69</a>]. However, since these studies excluded females with urinary tract abnormalities, immunocompromising conditions, or poorly controlled diabetes mellitus, it is reasonable to use a longer duration of therapy (eg, 7 days) in females with such comorbidities. Management issues in older adults are discussed further elsewhere. (See  <a class="medical medical_review" href="/z/d/html/14606.html" rel="external">"Approach to infection in the older adult", section on 'Urinary tract infection'</a>.)</p><p>If there is diagnostic uncertainty regarding cystitis versus early pyelonephritis, we treat the patient as having an acute complicated UTI (which includes pyelonephritis). In particular, the use of <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">nitrofurantoin</a>, <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">fosfomycin</a>, and <a class="drug drug_general" data-topicid="118047" href="/z/d/drug information/118047.html" rel="external">pivmecillinam</a> should be avoided in such cases because they do not achieve adequate renal tissue levels [<a href="#rid1">1</a>]. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents", section on 'Management'</a>.)</p><p class="headingAnchor" id="H1112172929"><span class="h4">Alternative antimicrobial options</span><span class="headingEndMark"> — </span>If any factors (such as allergies or concern for resistance) preclude use of the above first-line antimicrobials, oral beta-lactams (other than <a class="drug drug_general" data-topicid="118047" href="/z/d/drug information/118047.html" rel="external">pivmecillinam</a>) are appropriate options, and if beta-lactams cannot be used, a fluoroquinolone is reasonable  (<a class="graphic graphic_algorithm graphicRef115993" href="/z/d/graphic/115993.html" rel="external">algorithm 1</a>).</p><p>Acceptable beta-lactam agents include <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a> (500 mg twice daily), <a class="drug drug_general" data-topicid="9224" href="/z/d/drug information/9224.html" rel="external">cefpodoxime</a> (100 mg twice daily), and <a class="drug drug_general" data-topicid="9212" href="/z/d/drug information/9212.html" rel="external">cefadroxil</a> (500 mg twice daily), each given for five to seven days [<a href="#rid58">58,70,71</a>]. A shorter course is not adequate; in one trial, cefpodoxime did not meet criteria for noninferiority to <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> for clinical cure when each was given for three days [<a href="#rid72">72</a>]. Other beta-lactams, such as <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">cephalexin</a> (500 mg twice daily [<a href="#rid73">73</a>]), are less well studied but may be acceptable. Although <a class="drug drug_general" data-topicid="8602" href="/z/d/drug information/8602.html" rel="external">cefdinir</a> (300 mg twice daily) does not achieve high urinary concentrations, it may be sufficient to treat cystitis with susceptible organisms. <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">Ampicillin</a> or <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a> should <strong>not</strong> be used for empiric treatment given the high prevalence of resistance to these agents [<a href="#rid16">16-19,59</a>]. In general, beta-lactams are second-line agents because they are less effective and have more potential adverse effects than other UTI antimicrobials [<a href="#rid59">59,71,74,75</a>]. </p><p>If beta-lactams cannot be used (eg, because of severe allergy), <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> (250 mg twice daily or 500 mg extended release daily) and <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a> (250 mg daily), each for three days, are reasonable alternative agents. Other less commonly used fluoroquinolones that are effective include <a class="drug drug_general" data-topicid="9715" href="/z/d/drug information/9715.html" rel="external">ofloxacin</a> and <a class="drug drug_general" data-topicid="9710" href="/z/d/drug information/9710.html" rel="external">norfloxacin</a>. <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">Moxifloxacin</a> attains lower urinary levels than other fluoroquinolones and should not be used. Multiple randomized trials have demonstrated that fluoroquinolones are very effective for treatment of acute cystitis, and that fluoroquinolones are more effective than beta-lactams [<a href="#rid57">57,66,70,71,76-81</a>]. However, increasing rates of resistance mitigate the utility of the fluoroquinolone class. Furthermore, because of concerns about the adverse effects of fluoroquinolones, the risk-benefit balance for acute cystitis favors the use of fluoroquinolones only if other agents (including beta-lactams) cannot be used. When possible, fluoroquinolones should be reserved for more serious infections than acute simple cystitis [<a href="#rid82">82,83</a>]. If a fluoroquinolone is used, patients should be advised about the uncommon but potentially serious musculoskeletal and neurologic adverse effects. (See  <a class="medical medical_review" href="/z/d/html/490.html" rel="external">"Fluoroquinolones", section on 'Benefits and risks of use'</a>.)</p><p>If a patient has reasons not to use any of the first-line agents, beta-lactams, or fluoroquinolones, we obtain urine culture and susceptibility testing and treat empirically with an agent that was initially avoided because of concerns for possible resistance while awaiting those results. Alternately, if there are concerns about potential treatment failure with oral agents in patients with risk factors for more serious infection (eg, an underlying urologic condition or immunocompromising condition), the patient can be treated with an initial parenteral agent (which could be an intramuscular antibiotic), as in our approach to complicated UTI. (See  <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents", section on 'Outpatients'</a>.)</p><p>Another option for otherwise healthy individuals with relatively mild or ambivalent symptoms is to wait to treat until culture results can guide antibiotic selection. For acute simple cystitis, studies among females without comorbidities have suggested that deferring antimicrobial therapy until these results are available is a safe strategy [<a href="#rid84">84</a>]. Analgesics can be used for symptomatic therapy in the interim. (See <a class="local">'Directed antimicrobial selection'</a> below and <a class="local">'Antimicrobial sparing strategies'</a> below.)</p><p class="headingAnchor" id="H88979215"><span class="h3">Patients with MDR risk factors</span><span class="headingEndMark"> — </span>For patients who have risk factors for an MDR gram-negative infection  (<a class="graphic graphic_table graphicRef114310" href="/z/d/graphic/114310.html" rel="external">table 2</a>), we first obtain urine culture and susceptibility testing  (<a class="graphic graphic_algorithm graphicRef115993" href="/z/d/graphic/115993.html" rel="external">algorithm 1</a>). For empiric treatment, oral options include <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">nitrofurantoin</a> monohydrate/macrocrystals (Macrobid, 100 mg orally twice daily for five days), <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">fosfomycin</a> (3 g of powder mixed in water as a single dose), or, if available, <a class="drug drug_general" data-topicid="118047" href="/z/d/drug information/118047.html" rel="external">pivmecillinam</a> (400 mg orally three times daily for three to five days), unless the patient has a history of an isolate with documented resistance to these agents in the prior three months. If all these are appropriate options based on patient circumstances (allergies, intolerances, drug interactions) and prior urinary isolates, we suggest nitrofurantoin. We favor reserving the use of fosfomycin for documented MDR gram-negative infections or when nitrofurantoin is not an option, and pivmecillinam is not as effective. In the United States, resistance to all oral options is still uncommon among outpatients with <em>E. coli</em> cystitis.</p><p>Studies have suggested that <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">nitrofurantoin</a>, <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">fosfomycin</a>, and <a class="drug drug_general" data-topicid="118047" href="/z/d/drug information/118047.html" rel="external">pivmecillinam</a> still retain clinical activity against some MDR organisms, including ESBL-producing isolates [<a href="#rid35">35,74,85,86</a>]. As an example, in a case-control study including 113 patients with ESBL-producing <em>E. coli</em> UTIs, no resistance to fosfomycin was detected and clinical cure rates were high (93 percent) [<a href="#rid74">74</a>]. Some studies have evaluated a higher dose of fosfomycin (eg, 3 g once every 2 to 3 days for 3 doses) for infections due to MDR organisms, but there is no evidence that this has greater efficacy than single-dose therapy [<a href="#rid87">87,88</a>]. </p><p>If none of these can be used because of resistance or other concerns, we treat empirically with an agent that was initially avoided because of concerns for possible resistance while awaiting results of culture and susceptibility testing. Alternately, if there are concerns about potential treatment failure with oral agents in patients with risk factors for more serious infection (eg, an underlying urologic condition or immunocompromising condition), the patient can be treated with an initial parenteral agent (which could be an intramuscular antibiotic), as in our approach to complicated UTI. (See  <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents", section on 'Outpatients'</a>.)</p><p>Another option for otherwise healthy individuals with relatively mild or ambivalent symptoms is to wait to treat until culture results can guide antibiotic selection. For acute simple cystitis, studies among females without comorbidities have suggested that deferring antimicrobial therapy until these results are available is a safe strategy [<a href="#rid84">84</a>]. Analgesics can be used for symptomatic therapy in the interim. (See <a class="local">'Directed antimicrobial selection'</a> below and <a class="local">'Antimicrobial sparing strategies'</a> below.)</p><p class="headingAnchor" id="H1089116003"><span class="h2">Directed antimicrobial selection</span><span class="headingEndMark"> — </span>Acute simple cystitis in females is often treated empirically without culture and susceptibility testing. If such testing was performed (eg, because of risk for resistance or severe infection), those results can be used to inform regimen selection or adjustment. If susceptibility of the isolate allows, the approach to antimicrobial selection generally follows the same preferences as for empiric antimicrobial regimen selection, with <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">nitrofurantoin</a>, <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">fosfomycin</a>, and, if available, <a class="drug drug_general" data-topicid="118047" href="/z/d/drug information/118047.html" rel="external">pivmecillinam</a> as the preferred agents, followed by beta-lactams, followed by fluoroquinolones  (<a class="graphic graphic_table graphicRef143609" href="/z/d/graphic/143609.html" rel="external">table 4</a>). However, if urine culture demonstrates an organism resistant to an empirically chosen antibiotic, the regimen does not have to be adjusted if symptoms of cystitis have already resolved; patients should be counseled to return to care for recurrent symptoms.</p><p>If an <em>Enterococcus</em> or Group B <em>Streptococcus</em> grows as the only isolate on culture and is determined to be the cause of cystitis, <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a> (500 mg orally every eight hours or 875 mg twice daily for five days) is usually the preferred agent, as long as the isolate is susceptible. (See  <a class="medical medical_review" href="/z/d/html/3163.html" rel="external">"Treatment of enterococcal infections", section on 'Urinary tract infection'</a> and  <a class="medical medical_review" href="/z/d/html/3171.html" rel="external">"Group B streptococcal infections in nonpregnant adults", section on 'Regimen selection'</a>.)</p><p>If the patient cannot use any of the above options because of resistance or allergies to antibiotics, options are limited. In patients who have severe or highly bothersome symptoms, the most reliable approach is to treat with a parenteral agent (for at least the first dose), as for acute complicated UTI. Such regimens are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents", section on 'Outpatients'</a>.)</p><p>However, for patients with milder symptoms, it is reasonable to try to treat with oral agents of uncertain efficacy with or without analgesic rather than proceed to a parenteral agent. As an example, if the isolate is susceptible to <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>, a trial of that agent is reasonable, although data in UTI are sparse [<a href="#rid89">89</a>]. Otherwise, even if an isolate is resistant to <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> or a fluoroquinolone, using one of these still has the potential to be effective since these agents obtain high levels in the urine. Alternatively, deferring therapy for mild symptoms is also a reasonable approach for amenable patients, as symptoms can resolve spontaneously in some. </p><p class="headingAnchor" id="H4088013911"><span class="h2">Antimicrobial sparing strategies</span><span class="headingEndMark"> — </span>Given that acute simple cystitis is associated with increasing antimicrobial resistance and has a low risk of progression to invasive disease in patients without risk factors for serious infection, antimicrobial sparing management strategies (eg, anti-inflammatory drugs or delayed treatment) for some females with simple cystitis are of increasing interest but warrant further study before they can be routinely employed [<a href="#rid84">84,90,91</a>]. </p><p>Delaying antimicrobial therapy while awaiting urine culture results appears to be a reasonable approach in females without comorbidities if empiric therapy is complicated by resistance or drug intolerance. In a randomized trial of nonpregnant females &lt;75 years of age with acute simple cystitis, symptom duration and severity were similar with immediate antimicrobial therapy compared with four other strategies, including delayed antimicrobial therapy and antimicrobial therapy based on a symptom score, urinalysis findings, or urine culture results [<a href="#rid84">84</a>]. In a systematic review of three trials of cystitis, approximately one-third of those in the placebo or no treatment group had symptom resolution by seven days [<a href="#rid92">92</a>]. Although a large retrospective database analysis of patients ≥65 years of age with lower urinary tract infection suggested an association between delaying antimicrobial therapy and subsequent bloodstream infection within 60 days, multiple limitations of this study reduce confidence in the findings; these include potential misdiagnosis of cystitis, important and potentially confounding differences between groups, and failure to link the microbiology of the cystitis to bacteremia [<a href="#rid93">93</a>]. </p><p>Substituting anti-inflammatory agents for antimicrobial therapy has also been evaluated but, pending additional data, cannot be recommended as an initial approach to management of symptomatic acute simple cystitis. In one trial of 241 females with acute simple cystitis without risk factors for complications, those randomly assigned to treatment with <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a> (400 mg three times daily for three days) had a higher mean symptom burden compared with those who received <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">fosfomycin</a> as a single 3 g dose [<a href="#rid91">91</a>]. Fewer females in the ibuprofen group received any antimicrobials compared with the fosfomycin group (35 versus 100 percent), but they were more likely to require additional therapy with antimicrobials in follow-up and had a higher rate of serious adverse events, including five cases of pyelonephritis (2 percent) compared with one case (0.4 percent) in the fosfomycin group. Similar findings were observed in a trial comparing <a class="drug drug_general" data-topicid="9348" href="/z/d/drug information/9348.html" rel="external">diclofenac</a> with <a class="drug drug_general" data-topicid="9710" href="/z/d/drug information/9710.html" rel="external">norfloxacin</a> [<a href="#rid94">94</a>].</p><p class="headingAnchor" id="H2588420617"><span class="h2">Other interventions</span></p><p class="headingAnchor" id="H1127364673"><span class="h3">Symptomatic therapy</span><span class="headingEndMark"> — </span>Symptoms of acute simple cystitis should respond to antimicrobial therapy within 48 hours. In fact, dysuria is usually diminished within a few hours after the start of antimicrobial therapy [<a href="#rid95">95</a>]. In the interim, for some patients with severe dysuria, a urinary analgesic such as over-the-counter oral <a class="drug drug_general" data-topicid="9761" href="/z/d/drug information/9761.html" rel="external">phenazopyridine</a> three times daily as needed may be useful to relieve discomfort. A two-day course is usually sufficient to allow time for symptomatic response to antimicrobial therapy and minimize inflammation. Phenazopyridine should not be used chronically since it may mask clinical symptoms requiring clinical evaluation.</p><p class="headingAnchor" id="H4146053135"><span class="h3">Patients with urologic abnormalities</span><span class="headingEndMark"> — </span>In many cases, patients with underlying functional or anatomic urinary tract abnormalities (such as an indwelling catheter, urethral stent, neurogenic bladder, nephrolithiasis) have systemic symptoms (such as fever or autonomic dysreflexia) in the setting of UTI and are thus managed as having a complicated UTI. (See  <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents", section on 'Management'</a>.)</p><p>For those who appear to have only acute simple cystitis without upper tract or systemic symptoms, we believe that it is reasonable to cautiously treat them as outlined above. However, because these patients were not included in efficacy studies of the regimens we use for simple cystitis, we monitor them carefully for treatment failure (eg, persistent symptoms after initiation of empiric therapy) and follow initial urine cultures to ensure that the empirically chosen regimen was appropriate. Furthermore, since the antimicrobial durations listed above have not been well studied in patients with urologic dysfunction, a longer duration of therapy (eg, one to two weeks, depending on the agent chosen) is reasonable. It is also reasonable to have a lower threshold to treat such patients as having a complicated UTI (eg, for more subtle symptoms of pyelonephritis or systemic infection).</p><p>In addition, other treatment measures in addition to antimicrobial therapy may be warranted. These include more frequent intermittent catheterization, changing out an indwelling catheter prior to obtaining a urine culture (particularly if it has been in place for longer than one or two weeks), or urologic/urogynecologic consultation. </p><p class="headingAnchor" id="H899949241"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>Follow-up urine cultures are not needed in patients with acute simple cystitis whose symptoms resolve on antimicrobials. For patients who had hematuria on initial presentation, a urinalysis should be repeated several weeks following antimicrobial therapy to evaluate for persistent hematuria. (See  <a class="medical medical_review" href="/z/d/html/7208.html" rel="external">"Etiology and evaluation of hematuria in adults", section on 'Overall approach to the evaluation'</a>.)</p><p>Patients who have persistent symptoms after 48 to 72 hours of empiric antimicrobial therapy or have recurrent symptoms within a few weeks of treatment should have additional evaluation for other potential conditions that may be causing those symptoms and for factors that might be compromising clinical response. This includes urine culture and empiric treatment with another antimicrobial agent. Subsequent treatment should be tailored to the susceptibility profile of the causative organism isolated (see <a class="local">'Directed antimicrobial selection'</a> above). If symptoms persist in the setting of appropriate antimicrobial therapy, urologic assessment and radiographic imaging (generally with computed tomography) may be appropriate to evaluate for anatomic abnormalities that would interfere with response to antimicrobial treatment. Diagnoses other than cystitis should also be reconsidered  (<a class="graphic graphic_table graphicRef143594" href="/z/d/graphic/143594.html" rel="external">table 3</a>). </p><p>Patients with multiple recurrent episodes of cystitis (eg, ≥2 episodes in six months or ≥3 in one year) should be evaluated for preventive strategies. These are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8053.html" rel="external">"Recurrent simple cystitis in women", section on 'Evaluation'</a>.)</p><p class="headingAnchor" id="H1392300723"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111611.html" rel="external">"Society guideline links: Urinary tract infections in adults"</a>.)</p><p class="headingAnchor" id="H899949255"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/15353.html" rel="external">"Patient education: Urinary tract infections in adults (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/4016.html" rel="external">"Patient education: Urinary tract infections in adolescents and adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H899949262"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Terminology</strong> – We use the term “acute simple cystitis” to refer to an acute urinary tract infection (UTI) that is confined to the bladder in a nonpregnant individual  (<a class="graphic graphic_table graphicRef117508" href="/z/d/graphic/117508.html" rel="external">table 1</a>). Features suggesting that infection extends beyond the bladder are absent. These include fever (&gt;99.9°F/37.7°C) or other features of systemic infection, flank pain, and costovertebral angle tenderness. (See <a class="local">'Terminology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiology</strong> – <em>Escherichia coli</em> is the most frequent microbial cause of cystitis. Other common causes include <em>Klebsiella pneumoniae</em>, <em>Proteus mirabilis</em>, and <em>Staphylococcus saprophyticus. </em>Risk factors for UTI with resistant organisms include recent antimicrobial use, health care exposures, and travel to parts of the world where multidrug-resistant (MDR) organisms are prevalent  (<a class="graphic graphic_table graphicRef114310" href="/z/d/graphic/114310.html" rel="external">table 2</a>). (See <a class="local">'Microbiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – The classic manifestations of acute simple cystitis consist of dysuria, urinary frequency, urinary urgency, and suprapubic pain. Gross hematuria can also occur. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1">In older individuals, the symptoms of acute cystitis can be difficult to distinguish from nonspecific, noninfectious urinary symptoms (such as chronic dysuria or urinary incontinence). </p><p></p><p class="bulletIndent1">On urinalysis, pyuria is almost always present. (See <a class="local">'Urinalysis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical suspicion and diagnosis </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Individuals with classic cystitis symptoms</strong> – For females with new onset dysuria, urgency, frequency, and/or suprapubic discomfort, the diagnosis can generally be made on these features alone. Although we typically obtain urine studies for the first presentation to establish the presence of pyuria and bacteriuria, urine testing is otherwise not necessary to confirm the diagnosis with classic symptoms. Vaginal pruritus or discharge warrant pelvic examination to evaluate for vaginitis  (<a class="graphic graphic_table graphicRef143594" href="/z/d/graphic/143594.html" rel="external">table 3</a>). (See <a class="local">'Clinical suspicion and evaluation'</a> above.)</p><p></p><p class="bulletIndent2">Urine culture and susceptibility testing are also unnecessary for management in most, but we perform them in females with risk factors for resistant infection  (<a class="graphic graphic_table graphicRef114310" href="/z/d/graphic/114310.html" rel="external">table 2</a>) or more serious infection (eg, underlying urologic abnormalities, immunocompromising conditions, and poorly controlled diabetes mellitus). (See <a class="local">'Urine culture'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Individuals with atypical urinary symptoms</strong> – For females with urinary symptoms such as acute or chronic symptoms or new incontinence, we check a urinalysis (either by microscopy or by dipstick) and urine culture with susceptibility testing. The diagnosis of cystitis is made if pyuria and bacteriuria are present; their absence suggests an alternate diagnosis  (<a class="graphic graphic_table graphicRef143594" href="/z/d/graphic/143594.html" rel="external">table 3</a>). (See <a class="local">'Performing and interpreting urine studies'</a> above.)</p><p></p><p class="bulletIndent2">Chronic nocturia, chronic incontinence, general malaise, and cloudy or malodorous urine are nonspecific findings that should not routinely prompt urine testing to evaluate for cystitis. We also do not routinely test urine in elderly or debilitated patients with nonspecific changes in mental or functional status in the absence of focal urinary tract symptoms or systemic signs of infection. (See <a class="local">'Clinical suspicion and evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Exclude complicated UTI</strong> – Features of systemic infection (eg, chills, rigors, or new marked fatigue or malaise), flank pain, and costovertebral angle tenderness should prompt examination for fever, costovertebral angle tenderness, and abdominal tenderness beyond the suprapubic area; all these features should raise suspicion for acute complicated UTI, which is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents", section on 'Diagnostic approach'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Asymptomatic bacteriuria</strong> – In the absence of consistent urinary symptoms, any amount of bacteriuria (with or without pyuria) is <strong>not </strong>diagnostic of cystitis. (See  <a class="medical medical_review" href="/z/d/html/8061.html" rel="external">"Asymptomatic bacteriuria in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empiric antimicrobial selection</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients without MDR risk factors </strong>– For females without risk factors for a multidrug-resistant (MDR) gram-negative infection  (<a class="graphic graphic_table graphicRef114310" href="/z/d/graphic/114310.html" rel="external">table 2</a>), we suggest <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">nitrofurantoin</a> or <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>  (<a class="graphic graphic_table graphicRef143609" href="/z/d/graphic/143609.html" rel="external">table 4</a> and <a class="graphic graphic_algorithm graphicRef115993" href="/z/d/graphic/115993.html" rel="external">algorithm 1</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). These are first-line antimicrobials, which strike a balance between efficacy and adverse effects (including selection of resistant organisms). </p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">Fosfomycin</a> and <a class="drug drug_general" data-topicid="118047" href="/z/d/drug information/118047.html" rel="external">pivmecillinam</a> (not available in the United States) are other first-line options, but they may be slightly less effective. In addition, we reserve fosfomycin when needed for those with MDR risk, as overuse may increase resistance rates.</p><p></p><p class="bulletIndent2">Oral beta-lactams are appropriate alternative options for those who cannot use any of the first-line antimicrobials. If a beta-lactam cannot be used, fluoroquinolones are reasonable; however, they should be reserved for more serious infections than acute simple cystitis, if possible, because of concerns of adverse effects. (See <a class="local">'Patients without MDR risk factors'</a> above.) <span class="utd-adt-cnt utd-adt-pathwys utd-content-120491">(Related Pathway(s):  <a class="utd-content-120491" href="/pathway/120491?topicRef=8063&amp;source=see_link">Urinary tract infection (UTI): Empiric antibiotic selection for acute simple cystitis in female adults</a>.)</span></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with MDR risk factors </strong>–<strong> </strong>For females with risk factors for an MDR gram-negative infection  (<a class="graphic graphic_table graphicRef114310" href="/z/d/graphic/114310.html" rel="external">table 2</a>), we suggest <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">nitrofurantoin</a>  (<a class="graphic graphic_table graphicRef143609" href="/z/d/graphic/143609.html" rel="external">table 4</a> and <a class="graphic graphic_algorithm graphicRef115993" href="/z/d/graphic/115993.html" rel="external">algorithm 1</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Other oral options for MDR organisms include <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">fosfomycin</a> and <a class="drug drug_general" data-topicid="118047" href="/z/d/drug information/118047.html" rel="external">pivmecillinam</a> (not available in the United States), but these may not be as effective. (See <a class="local">'Patients with MDR risk factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>If no oral option seems appropriate </strong>–<strong> </strong>If no oral agents are appropriate because of resistance or other concerns, options include using one of the preferred oral regimens for simple cystitis despite potential resistance  (<a class="graphic graphic_table graphicRef143609" href="/z/d/graphic/143609.html" rel="external">table 4</a>) or using an initial dose of a parenteral agent used for acute complicated UTI. Deferring antimicrobial therapy until a regimen can be selected based on results of culture and susceptibility testing may be a reasonable alternative for otherwise healthy patients with mild or ambivalent symptoms. (See  <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents", section on 'Outpatients'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Directed antimicrobial therapy </strong>– If urine culture and susceptibility testing were performed (eg, because of risk for resistance or severe infection), those results can be used to inform regimen selection or adjustment, if needed. If susceptibility of the isolate allows, treatment options in order of decreasing preference are  (<a class="graphic graphic_table graphicRef143609" href="/z/d/graphic/143609.html" rel="external">table 4</a>): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">Nitrofurantoin</a> or <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">Fosfomycin</a> or <a class="drug drug_general" data-topicid="118047" href="/z/d/drug information/118047.html" rel="external">pivmecillinam</a> (where available)</p><p class="bulletIndent2"><span class="glyph">•</span>Oral beta-lactams</p><p class="bulletIndent2"><span class="glyph">•</span>Fluoroquinolones </p><p></p><p class="bulletIndent1">If a patient who is empirically started on an antibiotic and urine culture later demonstrates an organism resistant to that antibiotic, the regimen does not have to be adjusted if symptoms of cystitis have resolved.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunctive therapies</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For severe discomfort</strong> – Cystitis symptoms start to decrease within a few hours of antimicrobial therapy and should improve by 24 to 48 hours. In the interim, a urinary analgesic such as <a class="drug drug_general" data-topicid="9761" href="/z/d/drug information/9761.html" rel="external">phenazopyridine</a> (up to three times daily) can reduce dysuria symptoms, if needed. (See <a class="local">'Symptomatic therapy'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For underlying urinary tract abnormalities</strong> – Patients who have acute simple cystitis in the setting of underlying functional or anatomic urinary tract abnormalities (such as an indwelling catheter, urethral stent, neurogenic bladder, history of nephrolithiasis) may warrant more frequent catheterization, changing out an indwelling catheter, or urologic/urogynecologic consultation. (See <a class="local">'Patients with urologic abnormalities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up </strong>–<strong> </strong>Follow-up urine cultures are unnecessary if symptoms resolve on antimicrobials. Persistent symptoms after 48 to 72 hours of empiric treatment or recurrent symptoms within a few weeks warrant urine culture and susceptibility testing. If symptoms persist despite appropriate antimicrobial therapy, imaging to evaluate for anatomic abnormalities is appropriate; diagnoses other than UTI should also be reconsidered  (<a class="graphic graphic_table graphicRef143594" href="/z/d/graphic/143594.html" rel="external">table 3</a>). For patients who had hematuria on initial presentation, a urinalysis should be repeated several weeks following treatment to ensure resolution (See <a class="local">'Follow-up'</a> above.) </p><p></p><p class="headingAnchor" id="H1088804473"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Thomas M Hooton, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52:e103.</a></li><li><a class="nounderline abstract_t">Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am 2014; 28:1.</a></li><li><a class="nounderline abstract_t">Schappert SM, Rechtsteiner EA. Ambulatory medical care utilization estimates for 2007. Vital Health Stat 13 2011; :1.</a></li><li><a class="nounderline abstract_t">Hooton TM, Scholes D, Hughes JP, et al. A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med 1996; 335:468.</a></li><li><a class="nounderline abstract_t">Scholes D, Hooton TM, Roberts PL, et al. Risk factors associated with acute pyelonephritis in healthy women. Ann Intern Med 2005; 142:20.</a></li><li><a class="nounderline abstract_t">Czaja CA, Scholes D, Hooton TM, Stamm WE. Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis 2007; 45:273.</a></li><li><a class="nounderline abstract_t">Echols RM, Tosiello RL, Haverstock DC, Tice AD. Demographic, clinical, and treatment parameters influencing the outcome of acute cystitis. Clin Infect Dis 1999; 29:113.</a></li><li><a class="nounderline abstract_t">Hooton TM. Clinical practice. Uncomplicated urinary tract infection. N Engl J Med 2012; 366:1028.</a></li><li><a class="nounderline abstract_t">Gupta K, Trautner B. In the clinic. Urinary tract infection. Ann Intern Med 2012; 156:ITC3.</a></li><li><a class="nounderline abstract_t">Hooton TM, Roberts PL, Cox ME, Stapleton AE. Voided midstream urine culture and acute cystitis in premenopausal women. N Engl J Med 2013; 369:1883.</a></li><li><a class="nounderline abstract_t">Khawcharoenporn T, Vasoo S, Singh K. Urinary Tract Infections due to Multidrug-Resistant Enterobacteriaceae: Prevalence and Risk Factors in a Chicago Emergency Department. Emerg Med Int 2013; 2013:258517.</a></li><li><a class="nounderline abstract_t">Killgore KM, March KL, Guglielmo BJ. Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann Pharmacother 2004; 38:1148.</a></li><li><a class="nounderline abstract_t">Walker E, Lyman A, Gupta K, et al. Clinical Management of an Increasing Threat: Outpatient Urinary Tract Infections Due to Multidrug-Resistant Uropathogens. Clin Infect Dis 2016; 63:960.</a></li><li><a class="nounderline abstract_t">Smithson A, Chico C, Ramos J, et al. Prevalence and risk factors for quinolone resistance among Escherichia coli strains isolated from males with community febrile urinary tract infection. Eur J Clin Microbiol Infect Dis 2012; 31:423.</a></li><li><a class="nounderline abstract_t">Linsenmeyer K, Strymish J, Gupta K. Two Simple Rules for Improving the Accuracy of Empiric Treatment of Multidrug-Resistant Urinary Tract Infections. Antimicrob Agents Chemother 2015; 59:7593.</a></li><li><a class="nounderline abstract_t">Kahlmeter G. Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO.SENS study. Int J Antimicrob Agents 2003; 22 Suppl 2:49.</a></li><li><a class="nounderline abstract_t">Kahlmeter G, ECO.SENS. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J Antimicrob Chemother 2003; 51:69.</a></li><li><a class="nounderline abstract_t">Naber KG, Schito G, Botto H, et al. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol 2008; 54:1164.</a></li><li><a class="nounderline abstract_t">Zhanel GG, Hisanaga TL, Laing NM, et al. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 2006; 27:468.</a></li><li><a class="nounderline abstract_t">Sanchez GV, Master RN, Karlowsky JA, Bordon JM. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob Agents Chemother 2012; 56:2181.</a></li><li><a class="nounderline abstract_t">Swami SK, Liesinger JT, Shah N, et al. Incidence of antibiotic-resistant Escherichia coli bacteriuria according to age and location of onset: a population-based study from Olmsted County, Minnesota. Mayo Clin Proc 2012; 87:753.</a></li><li><a class="nounderline abstract_t">Gupta K, Hooton TM, Miller L, Uncomplicated UTI IDSA Guideline Committee. Managing uncomplicated urinary tract infection--making sense out of resistance data. Clin Infect Dis 2011; 53:1041.</a></li><li><a class="nounderline abstract_t">Richards DA, Toop LJ, Chambers ST, et al. Antibiotic resistance in uncomplicated urinary tract infection: problems with interpreting cumulative resistance rates from local community laboratories. N Z Med J 2002; 115:12.</a></li><li><a class="nounderline abstract_t">Ti TY, Kumarasinghe G, Taylor MB, et al. What is true community-acquired urinary tract infection? Comparison of pathogens identified in urine from routine outpatient specimens and from community clinics in a prospective study. Eur J Clin Microbiol Infect Dis 2003; 22:242.</a></li><li><a class="nounderline abstract_t">Brown PD, Freeman A, Foxman B. Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan. Clin Infect Dis 2002; 34:1061.</a></li><li><a class="nounderline abstract_t">Metlay JP, Strom BL, Asch DA. Prior antimicrobial drug exposure: a risk factor for trimethoprim-sulfamethoxazole-resistant urinary tract infections. J Antimicrob Chemother 2003; 51:963.</a></li><li><a class="nounderline abstract_t">Colgan R, Johnson JR, Kuskowski M, Gupta K. Risk factors for trimethoprim-sulfamethoxazole resistance in patients with acute uncomplicated cystitis. Antimicrob Agents Chemother 2008; 52:846.</a></li><li><a class="nounderline abstract_t">Olson RP, Harrell LJ, Kaye KS. Antibiotic resistance in urinary isolates of Escherichia coli from college women with urinary tract infections. Antimicrob Agents Chemother 2009; 53:1285.</a></li><li><a class="nounderline abstract_t">Gupta K. Emerging antibiotic resistance in urinary tract pathogens. Infect Dis Clin North Am 2003; 17:243.</a></li><li><a class="nounderline abstract_t">Raz R, Chazan B, Kennes Y, et al. Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens. Clin Infect Dis 2002; 34:1165.</a></li><li><a class="nounderline abstract_t">Miller LG, Tang AW. Treatment of uncomplicated urinary tract infections in an era of increasing antimicrobial resistance. Mayo Clin Proc 2004; 79:1048.</a></li><li><a class="nounderline abstract_t">Talan DA, Krishnadasan A, Abrahamian FM, et al. Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. Clin Infect Dis 2008; 47:1150.</a></li><li><a class="nounderline abstract_t">Paterson DL. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004; 38 Suppl 4:S341.</a></li><li><a class="nounderline abstract_t">Schito GC, Naber KG, Botto H, et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents 2009; 34:407.</a></li><li><a class="nounderline abstract_t">Ho PL, Yip KS, Chow KH, et al. Antimicrobial resistance among uropathogens that cause acute uncomplicated cystitis in women in Hong Kong: a prospective multicenter study in 2006 to 2008. Diagn Microbiol Infect Dis 2010; 66:87.</a></li><li><a class="nounderline abstract_t">Lautenbach E. Editorial commentary: flying under the radar: the stealth pandemic of Escherichia coli sequence type 131. Clin Infect Dis 2013; 57:1266.</a></li><li><a class="nounderline abstract_t">Bent S, Nallamothu BK, Simel DL, et al. Does this woman have an acute uncomplicated urinary tract infection? JAMA 2002; 287:2701.</a></li><li><a class="nounderline abstract_t">Mody L, Juthani-Mehta M. Urinary tract infections in older women: a clinical review. JAMA 2014; 311:844.</a></li><li><a class="nounderline abstract_t">Juthani-Mehta M, Quagliarello V, Perrelli E, et al. Clinical features to identify urinary tract infection in nursing home residents: a cohort study. J Am Geriatr Soc 2009; 57:963.</a></li><li><a class="nounderline abstract_t">Sundvall PD, Ulleryd P, Gunnarsson RK. Urine culture doubtful in determining etiology of diffuse symptoms among elderly individuals: a cross-sectional study of 32 nursing homes. BMC Fam Pract 2011; 12:36.</a></li><li><a class="nounderline abstract_t">Sundvall PD, Elm M, Ulleryd P, et al. Interleukin-6 concentrations in the urine and dipstick analyses were related to bacteriuria but not symptoms in the elderly: a cross sectional study of 421 nursing home residents. BMC Geriatr 2014; 14:88.</a></li><li><a class="nounderline abstract_t">Dasgupta M, Brymer C, Elsayed S. Treatment of asymptomatic UTI in older delirious medical in-patients: A prospective cohort study. Arch Gerontol Geriatr 2017; 72:127.</a></li><li><a class="nounderline abstract_t">Potts L, Cross S, MacLennan WJ, Watt B. A double-blind comparative study of norfloxacin versus placebo in hospitalised elderly patients with asymptomatic bacteriuria. Arch Gerontol Geriatr 1996; 23:153.</a></li><li><a class="nounderline abstract_t">Nace DA, Drinka PJ, Crnich CJ. Clinical uncertainties in the approach to long term care residents with possible urinary tract infection. J Am Med Dir Assoc 2014; 15:133.</a></li><li><a class="nounderline abstract_t">Stamm WE. Measurement of pyuria and its relation to bacteriuria. Am J Med 1983; 75:53.</a></li><li><a class="nounderline abstract_t">Wilson ML, Gaido L. Laboratory diagnosis of urinary tract infections in adult patients. Clin Infect Dis 2004; 38:1150.</a></li><li><a class="nounderline abstract_t">Brosh-Nissimov T, Navon-Venezia S, Keller N, Amit S. Risk analysis of antimicrobial resistance in outpatient urinary tract infections of young healthy adults. J Antimicrob Chemother 2019; 74:499.</a></li><li><a class="nounderline abstract_t">Gupta K, Hooton TM, Roberts PL, Stamm WE. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. Arch Intern Med 2007; 167:2207.</a></li><li><a class="nounderline abstract_t">McKinnell JA, Stollenwerk NS, Jung CW, Miller LG. Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis. Mayo Clin Proc 2011; 86:480.</a></li><li><a class="nounderline abstract_t">Huttner A, Verhaegh EM, Harbarth S, et al. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother 2015; 70:2456.</a></li><li><a class="nounderline abstract_t">Hooton TM, Winter C, Tiu F, Stamm WE. Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women. JAMA 1995; 273:41.</a></li><li><a class="nounderline abstract_t">Singh N, Gandhi S, McArthur E, et al. Kidney function and the use of nitrofurantoin to treat urinary tract infections in older women. CMAJ 2015; 187:648.</a></li><li><a class="nounderline abstract_t">Oplinger M, Andrews CO. Nitrofurantoin contraindication in patients with a creatinine clearance below 60 mL/min: looking for the evidence. Ann Pharmacother 2013; 47:106.</a></li><li><a class="nounderline abstract_t">By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 2015; 63:2227.</a></li><li><a class="nounderline abstract_t">Santos JM, Batech M, Pelter MA, Deamer RL. Evaluation of the Risk of Nitrofurantoin Lung Injury and Its Efficacy in Diminished Kidney Function in Older Adults in a Large Integrated Healthcare System: A Matched Cohort Study. J Am Geriatr Soc 2016; 64:798.</a></li><li><a class="nounderline abstract_t">Arredondo-García JL, Figueroa-Damián R, Rosas A, et al. Comparison of short-term treatment regimen of ciprofloxacin versus long-term treatment regimens of trimethoprim/sulfamethoxazole or norfloxacin for uncomplicated lower urinary tract infections: a randomized, multicentre, open-label, prospective study. J Antimicrob Chemother 2004; 54:840.</a></li><li><a class="nounderline abstract_t">Iravani A, Klimberg I, Briefer C, et al. A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection. J Antimicrob Chemother 1999; 43 Suppl A:67.</a></li><li><a class="nounderline abstract_t">Kavatha D, Giamarellou H, Alexiou Z, et al. Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of uncomplicated acute cystitis in women. Antimicrob Agents Chemother 2003; 47:897.</a></li><li><a class="nounderline abstract_t">Warren JW, Abrutyn E, Hebel JR, et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999; 29:745.</a></li><li><a class="nounderline abstract_t">Stein GE. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther 1999; 21:1864.</a></li><li><a class="nounderline abstract_t">Falagas ME, Vouloumanou EK, Togias AG, et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010; 65:1862.</a></li><li><a class="nounderline abstract_t">Huttner A, Kowalczyk A, Turjeman A, et al. Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: A randomized clinical trial. JAMA 2018; doi:10.1001/jama.2018.3627.</a></li><li><a class="nounderline abstract_t">Datta R, Juthani-Mehta M. Nitrofurantoin vs Fosfomycin: Rendering a Verdict in a Trial of Acute Uncomplicated Cystitis. JAMA 2018; 319:1771.</a></li><li><a class="nounderline abstract_t">Jansåker F, Thønnings S, Hertz FB, et al. Three versus five days of pivmecillinam for community-acquired uncomplicated lower urinary tract infection: A randomised, double-blind, placebo-controlled superiority trial. EClinicalMedicine 2019; 12:62.</a></li><li><a class="nounderline abstract_t">Ferry SA, Holm SE, Stenlund H, et al. Clinical and bacteriological outcome of different doses and duration of pivmecillinam compared with placebo therapy of uncomplicated lower urinary tract infection in women: the LUTIW project. Scand J Prim Health Care 2007; 25:49.</a></li><li><a class="nounderline abstract_t">Nicolle LE, Madsen KS, Debeeck GO, et al. Three days of pivmecillinam or norfloxacin for treatment of acute uncomplicated urinary infection in women. Scand J Infect Dis 2002; 34:487.</a></li><li><a class="nounderline abstract_t">Graninger W. Pivmecillinam--therapy of choice for lower urinary tract infection. Int J Antimicrob Agents 2003; 22 Suppl 2:73.</a></li><li><a class="nounderline abstract_t">Lee RA, Centor RM, Humphrey LL, et al. Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the American College of Physicians. Ann Intern Med 2021; 174:822.</a></li><li><a class="nounderline abstract_t">Lutters M, Vogt-Ferrier NB. Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly women. Cochrane Database Syst Rev 2008; :CD001535.</a></li><li><a class="nounderline abstract_t">Auquer F, Cordón F, Gorina E, et al. Single-dose ciprofloxacin versus 3 days of norfloxacin in uncomplicated urinary tract infections in women. Clin Microbiol Infect 2002; 8:50.</a></li><li><a class="nounderline abstract_t">Hooton TM, Scholes D, Gupta K, et al. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. JAMA 2005; 293:949.</a></li><li><a class="nounderline abstract_t">Hooton TM, Roberts PL, Stapleton AE. Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial. JAMA 2012; 307:583.</a></li><li><a class="nounderline abstract_t">Yetsko A, Draper HM, Eid K, et al. Two Times Versus Four Times Daily Cephalexin Dosing for the Treatment of Uncomplicated Urinary Tract Infections in Females. Open Forum Infect Dis 2023; 10:ofad430.</a></li><li><a class="nounderline abstract_t">Rodríguez-Baño J, Alcalá JC, Cisneros JM, et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 2008; 168:1897.</a></li><li><a class="nounderline abstract_t">Butler AM, Durkin MJ, Keller MR, et al. Association of Adverse Events With Antibiotic Treatment for Urinary Tract Infection. Clin Infect Dis 2022; 74:1408.</a></li><li><a class="nounderline abstract_t">Henry D, Ellison W, Sullivan J, et al. Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi Center UUTI Study Group. Antimicrob Agents Chemother 1998; 42:2262.</a></li><li><a class="nounderline abstract_t">Richard GA, Mathew CP, Kirstein JM, et al. Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women: results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens. Urology 2002; 59:334.</a></li><li><a class="nounderline abstract_t">Fourcroy JL, Berner B, Chiang YK, et al. Efficacy and safety of a novel once-daily extended-release ciprofloxacin tablet formulation for treatment of uncomplicated urinary tract infection in women. Antimicrob Agents Chemother 2005; 49:4137.</a></li><li><a class="nounderline abstract_t">Henry DC Jr, Bettis RB, Riffer E, et al. Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women. Clin Ther 2002; 24:2088.</a></li><li><a class="nounderline abstract_t">Vogel T, Verreault R, Gourdeau M, et al. Optimal duration of antibiotic therapy for uncomplicated urinary tract infection in older women: a double-blind randomized controlled trial. CMAJ 2004; 170:469.</a></li><li><a class="nounderline abstract_t">Zalmanovici Trestioreanu A, Green H, Paul M, et al. Antimicrobial agents for treating uncomplicated urinary tract infection in women. Cochrane Database Syst Rev 2010; :CD007182.</a></li><li><a class="nounderline abstract_t">Hooton TM, Besser R, Foxman B, et al. Acute uncomplicated cystitis in an era of increasing antibiotic resistance: a proposed approach to empirical therapy. Clin Infect Dis 2004; 39:75.</a></li><li class="breakAll">US Food and Drug Administration. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm500143.htm (Accessed on May 26, 2016).</li><li><a class="nounderline abstract_t">Little P, Moore MV, Turner S, et al. Effectiveness of five different approaches in management of urinary tract infection: randomised controlled trial. BMJ 2010; 340:c199.</a></li><li><a class="nounderline abstract_t">Qiao LD, Chen S, Yang Y, et al. Characteristics of urinary tract infection pathogens and their in vitro susceptibility to antimicrobial agents in China: data from a multicenter study. BMJ Open 2013; 3:e004152.</a></li><li><a class="nounderline abstract_t">Jansåker F, Frimodt-Møller N, Sjögren I, Dahl Knudsen J. Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections. J Antimicrob Chemother 2014; 69:769.</a></li><li><a class="nounderline abstract_t">Loethen AA, Kerstenetzky L, Descourouez JL, et al. Fosfomycin for the Treatment of Cystitis in the Abdominal Solid Organ Transplant Population. Pharmacotherapy 2017; 37:599.</a></li><li><a class="nounderline abstract_t">Seroy JT, Grim SA, Reid GE, et al. Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis. J Antimicrob Chemother 2016; 71:2563.</a></li><li><a class="nounderline abstract_t">White CR, Jodlowski TZ, Atkins DT, Holland NG. Successful Doxycycline Therapy in a Patient With Escherichia coli and Multidrug-Resistant Klebsiella pneumoniae Urinary Tract Infection. J Pharm Pract 2017; 30:464.</a></li><li><a class="nounderline abstract_t">Bleidorn J, Gágyor I, Kochen MM, et al. Symptomatic treatment (ibuprofen) or antibiotics (ciprofloxacin) for uncomplicated urinary tract infection?--results of a randomized controlled pilot trial. BMC Med 2010; 8:30.</a></li><li><a class="nounderline abstract_t">Gágyor I, Bleidorn J, Kochen MM, et al. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. BMJ 2015; 351:h6544.</a></li><li><a class="nounderline abstract_t">Hoffmann T, Peiris R, Mar CD, et al. Natural history of uncomplicated urinary tract infection without antibiotics: a systematic review. Br J Gen Pract 2020; 70:e714.</a></li><li><a class="nounderline abstract_t">Gharbi M, Drysdale JH, Lishman H, et al. Antibiotic management of urinary tract infection in elderly patients in primary care and its association with bloodstream infections and all cause mortality: population based cohort study. BMJ 2019; 364:l525.</a></li><li><a class="nounderline abstract_t">Kronenberg A, Bütikofer L, Odutayo A, et al. Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial. BMJ 2017; 359:j4784.</a></li><li><a class="nounderline abstract_t">Klimberg I, Shockey G, Ellison H, et al. Time to symptom relief for uncomplicated urinary tract infection treated with extended-release ciprofloxacin: a prospective, open-label, uncontrolled primary care study. Curr Med Res Opin 2005; 21:1241.</a></li></ol></div><div id="topicVersionRevision">Topic 8063 Version 66.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21292654" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24484571" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21614897" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Ambulatory medical care utilization estimates for 2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8672152" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A prospective study of risk factors for symptomatic urinary tract infection in young women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15630106" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Risk factors associated with acute pyelonephritis in healthy women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17599303" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Population-based epidemiologic analysis of acute pyelonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10433573" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Demographic, clinical, and treatment parameters influencing the outcome of acute cystitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22417256" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical practice. Uncomplicated urinary tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22393148" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : In the clinic. Urinary tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24224622" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Voided midstream urine culture and acute cystitis in premenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24307946" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Urinary Tract Infections due to Multidrug-Resistant Enterobacteriaceae: Prevalence and Risk Factors in a Chicago Emergency Department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15150380" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27313263" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical Management of an Increasing Threat: Outpatient Urinary Tract Infections Due to Multidrug-Resistant Uropathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21761126" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prevalence and risk factors for quinolone resistance among Escherichia coli strains isolated from males with community febrile urinary tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26416859" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Two Simple Rules for Improving the Accuracy of Empiric Treatment of Multidrug-Resistant Urinary Tract Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14527771" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO.SENS study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12493789" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18511178" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16713191" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22252813" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22795635" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Incidence of antibiotic-resistant Escherichia coli bacteriuria according to age and location of onset: a population-based study from Olmsted County, Minnesota.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21940416" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Managing uncomplicated urinary tract infection--making sense out of resistance data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11936326" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Antibiotic resistance in uncomplicated urinary tract infection: problems with interpreting cumulative resistance rates from local community laboratories.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12709838" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : What is true community-acquired urinary tract infection? Comparison of pathogens identified in urine from routine outpatient specimens and from community clinics in a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11914994" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12654756" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Prior antimicrobial drug exposure: a risk factor for trimethoprim-sulfamethoxazole-resistant urinary tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18086847" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Risk factors for trimethoprim-sulfamethoxazole resistance in patients with acute uncomplicated cystitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19104022" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Antibiotic resistance in urinary isolates of Escherichia coli from college women with urinary tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12848469" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Emerging antibiotic resistance in urinary tract pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11941541" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15301333" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Treatment of uncomplicated urinary tract infections in an era of increasing antimicrobial resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18808361" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15127367" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : "Collateral damage" from cephalosporin or quinolone antibiotic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19505803" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19446980" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Antimicrobial resistance among uropathogens that cause acute uncomplicated cystitis in women in Hong Kong: a prospective multicenter study in 2006 to 2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23926177" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Editorial commentary: flying under the radar: the stealth pandemic of Escherichia coli sequence type 131.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12020306" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Does this woman have an acute uncomplicated urinary tract infection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24570248" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Urinary tract infections in older women: a clinical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19490243" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clinical features to identify urinary tract infection in nursing home residents: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21592413" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Urine culture doubtful in determining etiology of diffuse symptoms among elderly individuals: a cross-sectional study of 32 nursing homes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25117748" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Interleukin-6 concentrations in the urine and dipstick analyses were related to bacteriuria but not symptoms in the elderly: a cross sectional study of 421 nursing home residents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28624753" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Treatment of asymptomatic UTI in older delirious medical in-patients: A prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15374159" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A double-blind comparative study of norfloxacin versus placebo in hospitalised elderly patients with asymptomatic bacteriuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24461240" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Clinical uncertainties in the approach to long term care residents with possible urinary tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6349345" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Measurement of pyuria and its relation to bacteriuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15095222" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Laboratory diagnosis of urinary tract infections in adult patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30357329" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Risk analysis of antimicrobial resistance in outpatient urinary tract infections of young healthy adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17998493" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21576512" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26066581" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7654268" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25918178" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Kidney function and the use of nitrofurantoin to treat urinary tract infections in older women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23341159" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Nitrofurantoin contraindication in patients with a creatinine clearance below 60 mL/min: looking for the evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26446832" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27100576" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Evaluation of the Risk of Nitrofurantoin Lung Injury and Its Efficacy in Diminished Kidney Function in Older Adults in a Large Integrated Healthcare System: A Matched Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15347634" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Comparison of short-term treatment regimen of ciprofloxacin versus long-term treatment regimens of trimethoprim/sulfamethoxazole or norfloxacin for uncomplicated lower urinary tract infections: a randomized, multicentre, open-label, prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10225575" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12604518" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of uncomplicated acute cystitis in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10589881" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10890258" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20587612" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: A randomized clinical trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29710273" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Nitrofurantoin vs Fosfomycin: Rendering a Verdict in a Trial of Acute Uncomplicated Cystitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31388664" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Three versus five days of pivmecillinam for community-acquired uncomplicated lower urinary tract infection: A randomised, double-blind, placebo-controlled superiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17354160" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Clinical and bacteriological outcome of different doses and duration of pivmecillinam compared with placebo therapy of uncomplicated lower urinary tract infection in women: the LUTIW project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12195873" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Three days of pivmecillinam or norfloxacin for treatment of acute uncomplicated urinary infection in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14527775" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Pivmecillinam--therapy of choice for lower urinary tract infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33819054" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the American College of Physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18646074" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11906502" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Single-dose ciprofloxacin versus 3 days of norfloxacin in uncomplicated urinary tract infections in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15728165" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22318279" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Cefpodoxime vs ciprofloxacin for short-course treatment of acute uncomplicated cystitis: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37779597" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Two Times Versus Four Times Daily Cephalexin Dosing for the Treatment of Uncomplicated Urinary Tract Infections in Females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18809817" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34279560" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Association of Adverse Events With Antibiotic Treatment for Urinary Tract Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9736546" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Treatment of community-acquired acute uncomplicated urinary tract infection with sparfloxacin versus ofloxacin. The Sparfloxacin Multi Center UUTI Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11880065" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women: results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16189090" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Efficacy and safety of a novel once-daily extended-release ciprofloxacin tablet formulation for treatment of uncomplicated urinary tract infection in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12581547" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14970093" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Optimal duration of antibiotic therapy for uncomplicated urinary tract infection in older women: a double-blind randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20927755" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Antimicrobial agents for treating uncomplicated urinary tract infection in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15206056" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Acute uncomplicated cystitis in an era of increasing antibiotic resistance: a proposed approach to empirical therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15206056" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Acute uncomplicated cystitis in an era of increasing antibiotic resistance: a proposed approach to empirical therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20139214" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Effectiveness of five different approaches in management of urinary tract infection: randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24334199" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Characteristics of urinary tract infection pathogens and their in vitro susceptibility to antimicrobial agents in China: data from a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24107388" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28295441" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Fosfomycin for the Treatment of Cystitis in the Abdominal Solid Organ Transplant Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27246234" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27071978" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Successful Doxycycline Therapy in a Patient With Escherichia coli and Multidrug-Resistant Klebsiella pneumoniae Urinary Tract Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20504298" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Symptomatic treatment (ibuprofen) or antibiotics (ciprofloxacin) for uncomplicated urinary tract infection?--results of a randomized controlled pilot trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26698878" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32958533" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Natural history of uncomplicated urinary tract infection without antibiotics: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30814048" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Antibiotic management of urinary tract infection in elderly patients in primary care and its association with bloodstream infections and all cause mortality: population based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29113968" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Symptomatic treatment of uncomplicated lower urinary tract infections in the ambulatory setting: randomised, double blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16083534" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Time to symptom relief for uncomplicated urinary tract infection treated with extended-release ciprofloxacin: a prospective, open-label, uncontrolled primary care study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
